Olatec gets $40M to put an­ti-in­flam­ma­to­ry in late-stage tri­al; En­liv­en goes pub­lic, rais­es $165M

A US and Dutch biotech closed its $40 mil­lion Se­ries A to bankroll more stud­ies of its oral an­ti-in­flam­ma­to­ry drug.

Olatec Ther­a­peu­tics said the fi­nanc­ing will fund a late-stage clin­i­cal tri­al of its drug, da­pan­sutrile, an NL­RP3 in­hibitor. No­var­tis, Roche and No­vo Nordisk have all caught wind of the NL­RP3 space, with the lat­ter join­ing in via a deal with Ven­tus Ther­a­peu­tics in NASH and oth­er car­dio meta­bol­ic dis­eases.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN